Deep Tech · Formation to Series A+
Finding and funding the next generation
of $10B+ deep tech giants.
We are scientists who became founders.
Founders who became investors.
The greatest deep tech companies of the 2030s are being built right now — by founders who cannot yet access the capital they deserve. We find them first. We back them before de-risking strips the upside.
When founders hit the wall — the failed fundraise, the midnight pivot, the moment doubt becomes dangerous — we are the call they make. Not because we have a framework for it. Because we have lived it.
This is not a fund that follows trends.
This is a fund built to define them.
AI-designed proteins, digital twins and foundation models accelerating drug discovery. Automation compressing discovery-to-market timelines. The tools are already here — the exits will follow.
Defence and health ministries across Europe and the US are committing multi-billion budgets to domestic biotech capability. State-backed demand — the most durable signal in venture.
Next-generation gene and RNA therapies. Longevity platforms. Brain-computer interfaces moving from clinical to consumer this decade. We are early in both.
"The dendrite does not wait
to receive a signal.
It grows toward it."
DENDRITIC /den·drit·ik/ Derived from the Greek "dendron" (tree). In neuroscience, dendrites are the branching extensions of neurons that receive and integrate signals — forming complex, adaptive networks. We invest the same way: building richly connected, resilient portfolios that capture signal before the market does.
If you understand what we are building — or why the moment matters — we would like to hear from you.